drugset / Trial / NCT00030524
ZD 1839 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer
Phase 2
Completed
The University of Texas Health Science Center at San Antonio
National Cancer Institute (NCI) · collab
Open-labelTreatment
Summary
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of tumor cells and slow the growth of colorectal cancer. PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have locally advanced or metastatic colorectal cancer that has not responded to chemotherapy.
Timeline
- Start
- 2002-01
- Primary completion
- 2003-09
- Completion
- 2003-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gefitinib | Small molecule | — | Oral |